PubMed Health⌕ Search

Biomedical subjects

M N Zakharova

Publications and source records attributed to M N Zakharova.

At least 19 recordsLinked to original sources
PubMed2006

[A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].

A comparative analysis of efficacy and tolerability of such immunomodulating compounds as rebif 22-mcg and copaxone used in the treatment of multiple sclerosis is presented. The analysis was based on the data obtained in the 2-year study of copaxone (145 patients) and rebif 22-mcg (74 patients) therapy carried out in the Neurology Institute, Russian Academy of Medical Sciences.

Adjuvants, Immunologic↗
PubMed2005

[Structure of peripheral blood platelets surface in patients with amyotrophic lateral sclerosis and multiple sclerosis].

Using scanning electronic microscopy of peripheral blood platelets in 32 patients with amyotrophic lateral sclerosis (ALS) and 6 patients with multiple sclerosis (MS), platelets activation, emerging in pseudopodiums formation, aggregation and lysis, was found. Platelets activation was more pronounced in ALS than in MS. It was most markedly seen for quantitative evaluation of the above traits. The features of platelet activation found in the study support the evidence for considering ALS as a systemic disorder being characterized by a broad spectrum of alterations of biological processes.

Amyotrophic Lateral Sclerosis↗
PubMed2003

[Multiple sclerosis: etiology and pathogenesis].

Multiple sclerosis is the most frequent disease of the central nervous system. This review includes the last achievements in studies of the etiology and pathogenesis of this disease. Immune reactions was discussed as the main mechanism, which mediates the development of this disease. The peculiarities of the pathological process in different clinical types of the disease are discussed. Heterogenic mechanisms of damage of myelin oligodendrocytes and axons is the base for the elaboration of different approaches to MS treatment.

B-Lymphocytes↗
PubMed2003

[Results of a multicenter study of Rebif-22 mcg administration in Russia].

The results of multicenter study of Rebif 22 micrograms in Russia have been reported. 167 multiple sclerosis patients have received Rebif 22 micrograms three times a week for 1 year. This study provides evidence for reduction of the relapse rate in patients with relapsing/remitting and secondary progressive multiple sclerosis. The tendency to the decrease of the severity of relapses, less need for steroid use and the decrease of EDSS score in patients with relapsing/remitting multiple sclerosis have been shown. In general Rebif 22 micrograms was tolerated well.

Adjuvants, Immunologic↗
PubMed2002

[Progressive course of multiple sclerosis].

The mechanisms of MS progression are now studied with great attention and the treatment strategies at this stage of MS are widely discussed. The clinical peculiarities, genetic profile, immunological and biochemical changes, data of pathomorphological and MRI studies are discussed in this review. The data of own original immunological, biochemical and MRI studies, comparing relapsing-remitting and progressive MS course are presented. The role of axonal degeneration in the disease progression and data of the last trial of beta-interferons in secondary progressive MS are also discussed.

Adjuvants, Immunologic↗
PubMed2002

[Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis].

Results of the 2-year open postregistration study of Copaxone (glatiramer acetate), conducted in 3 Moscow leading medical centres are given. 32 MS patients with remitting-relapsing MS were investigated in accordance with international requirements (neurological scales, MRI of the brain, multimodal evoked potential). Significant reduction of annual relapse rate for 70.3%, stabilization of neurological status and benign safety profile were demonstrated during Copaxone treatment. Practical recommendations for Copaxone use are given.

Adjuvants, Immunologic↗
PubMed1999

[Neuronal death is basic problem of neurology and psychiatry].

The review deals with neuronal death in neurological and mental disorders. It considers two types of neuronal death in the central neuronal death: apoptosis and necrosis, as well as their mechanisms of development and regulation with the participation of apoptotic and antiapoptotic genes. At present, oxidative stress and excitotoxicity are considered to be the major mechanisms of cell death. Recent advances of molecular cell biology in the understanding the mechanisms responsible for neuronal death permit one to develop new therapeutical approaches in diseases of the central nervous system.

Cell Death↗
PubMed1992

[Pathogenesis of retrobulbar neuritis].

Biological fluids from 146 patients with retrobulbar neuritis were examined for the biochemical, immunochemical and immunologic characteristics that mirror destructive processes in myelin and changes in the system of the cholinoglycine cycle which is one of the stages of the synthesis of myelin in the oligodendrocyte. In the majority of observations, the changes in these reactions of different directions and of varying intensity were revealed. Based on the data obtained the conclusion is made that part of the patients with retrobulbar neuritis may be attributed to multiple sclerosis since according to the laboratory findings, the demyelinating process occurring in them goes beyond optic nerves. Besides, it has been shown with special reference to retrobulbar neuritis that the primary affect, possibly of the viral nature, is likely to be localized in the oligodendrocyte, with myelin being involved in the process for the second time.

Humans↗